



February 13, 2025

The Manager
BSE Limited
Corporate Relationship Department
P. J. Towers, Dalal Street,
Mumbai – 400 001.

The Manager
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051.

BSE Scrip Code No. 524280

NSE Symbol : KOPRAN

Dear Sir/Madam,

Sub: Integrated Filing (Financial) for the quarter ended and Nine Month ended December 31, 2024

Please find attached herewith the Integrated Filing(Financial) of Kopran Limited (“The Company”)for the quarter and nine months ended December 31,2024. The same is also being made available on the website of the Company at <https://www.kopran.com/> .

This disclosure is being made in compliance with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31,2024 read with Circular No. 20250102-4 issued by BSE Limited and Circular No. NSE/CML/2025/02 issued by the National Stock Exchange of India Limited, both circulars even dated January 2, 2025.

This is for your information and record.

Regards,
For Kopran Limited

Sunil Sodhani
Company Secretary & Compliance Officer
Membership No. FCS 3897

Encl : As above



KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111
Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078. E-mail: cs@kopran.com
Works:• Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337•Fax: (02192) 274025

KOPRAN LIMITED
STATEMENT OF CONSOLIDATED AND STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

(₹ in Lacs)

Particulars	Consolidated						Standalone											
	For the Quarter ended			For the Nine Months ended			For the Year ended			For the Quarter ended			For the Nine Months ended			For the Year ended		
	31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024	31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024	31/12/2024	30/09/2024	31/12/2023	31/12/2024	30/09/2024	31/12/2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
(1) Revenue from Operations	16,624.29	15,156.19	15,891.83	45,724.13	42,851.06	61,459.18	7,193.79	7,352.96	8,231.40	19,507.45	24,683.28	33,745.57						
(2) Other Income	17.17	14.94	29.38	151.98	47.63	744.14	42.68	39.71	39.88	229.44	567.88	1,234.98						
(3) Foreign Exchange Gain (Net)	-	84.56	213.42	-	446.91	716.95	31.88	72.43	89.15	169.25	288.29	436.10						
(4) Total Income (1+2+3)	16,641.46	15,255.69	16,134.63	45,876.11	43,345.60	62,920.27	7,268.35	7,465.10	8,362.43	19,906.14	25,539.45	35,416.65						
(5) Expenses																		
(a) Cost of materials consumed	9,675.09	10,354.10	10,891.44	29,180.41	28,878.12	39,485.42	3,600.98	4,190.84	4,804.09	10,975.61	16,079.86	21,753.66						
(b) Purchase of stock-in-trade	41.64	98.73	(225.70)	189.10	(104.91)	602.93	41.64	131.53	61.06	295.60	1,300.42	1,435.53						
(c) Changes in Inventories of finished goods, stock-in-trade and work-in-progress	853.75	(687.78)	(703.22)	(443.96)	(1,359.73)	105.56	579.06	25.16	251.60	91.06	(61.31)	(173.60)						
(d) Employee benefits expense	1,539.68	1,453.00	1,374.45	4,327.44	3,936.16	5,228.42	740.96	739.04	676.56	2,115.98	1,925.69	2,560.62						
(e) Finance costs	215.58	223.43	223.60	657.17	600.52	859.26	98.57	83.14	102.47	250.86	272.18	450.10						
(f) Depreciation and amortisation expense	399.68	385.49	326.57	1,172.55	929.32	1,288.72	133.19	123.06	117.21	375.96	345.88	462.04						
(g) Other expenses	2,223.00	2,464.26	2,196.71	6,889.83	6,229.35	8,595.49	1,091.20	1,297.67	1,233.64	3,392.45	3,280.09	4,476.77						
(h) Foreign Exchange Loss (Net)	307.18	-	-	79.88	-	-	-	-	-	-	-	-						
Total Expenses (5)	15,255.60	14,291.23	14,083.85	42,052.42	39,108.83	56,165.80	6,285.60	6,590.44	7,246.63	17,497.52	23,142.81	30,965.12						
(6) Profit before exceptional items and tax (4-5)	1,385.86	964.46	2,050.78	3,823.69	4,236.77	6,754.47	982.75	874.66	1,115.80	2,408.62	2,396.64	4,451.53						
(7) Exceptional items (Net)	-	-	-	-	-	-	-	-	-	-	-	-						
(8) Profit before tax (6-7)	1,385.86	964.46	2,050.78	3,823.69	4,236.77	6,754.47	982.75	874.66	1,115.80	2,408.62	2,396.64	4,451.53						
(9) Tax expense																		
(a) Current Tax	317.26	205.08	469.71	890.20	941.31	1,585.54	237.22	212.55	279.70	589.71	485.19	1,008.20						
(b) Deferred Tax	29.09	20.97	1.71	46.03	61.85	73.31	4.82	1.72	(15.03)	(6.78)	(21.33)	(20.29)						
(10) Profit for the period/year (8 - 9)	1,039.51	738.41	1,579.36	2,887.46	3,233.61	5,095.62	740.71	660.39	851.13	1,825.69	1,932.78	3,463.62						
(11) Other Comprehensive Income	10.40		15.79	28.87	32.34		7.41		8.51									
(i) Items that will not be reclassified to profit and loss																		
(a) - Remeasurements of defined benefit plans	5.44	5.45	4.57	16.34	13.74	21.78	2.55	2.56	2.51	7.66	7.53	10.21						
Income tax effect on Remeasurement of defined employee benefit plans	(1.38)	(1.33)	(1.17)	(4.10)	(3.52)	(5.58)	(0.65)	(0.62)	(0.64)	(1.92)	(1.93)	(2.62)						
(b) - Net changes in Fair value of investments in equity shares carried at fair value through OCI	-	-	-	-	-	-	-	-	-	-	-	-						
Income tax effect on Fair value of investments in equity shares carried at fair value through OCI	-	-	-	-	-	-	-	-	-	-	-	-						
ii) a) Items that will be reclassified to profit or loss																		
Exchange difference in translating the financial statements of foreign operation	7.39	0.06	1.24	7.99	4.50	4.41	-	-	-	-	-	-						
Other Comprehensive Income (11)	11.45	4.18	4.64	20.23	14.72	20.61	1.90	1.94	1.87	5.74	5.60	7.59						
(12) Total Comprehensive Income (10+11)	1,050.96	742.59	1,584.00	2,907.69	3,248.33	5,116.23	742.61	662.33	853.00	1,831.43	1,938.38	3,471.21						



[Handwritten Signature]




Profit attributable to													
- Owners of the Company	1,039.51	738.41	1,579.36	2,887.46	3,233.61	5,095.62	-	-	-	-	-	-	-
- Non - Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Comprehensive Income / (Loss) attributable to													
- Owners of the Company	16.05	4.18	4.64	20.23	14.72	20.61	-	-	-	-	-	-	-
- Non - Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Comprehensive Income attributable to													
- Owners of the Company	2,165.10	742.59	1,584.00	2,907.69	3,248.33	5,116.23	-	-	-	-	-	-	-
- Non - Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-	-
(13) Paid up Equity Share Capital (Face Value of Rs. 10 each)	4824.94	4824.94	4,821.06	4,821.06	4,821.06	4,821.06	4,821.06	4,821.06	4,821.06	4,821.06	4,821.06	4,821.06	4,821.06
(14) Other Equity							44,303.44						36,865.68
(15) Earnings Per Share (EPS) (Face value Rs. 10/- each)													
(a) Basic	2.16	1.53	3.28	5.99	6.71	10.57	1.54	1.37	1.77	3.79	4.01	7.18	
(b) Diluted	2.15	1.53	3.27	5.98	6.69	10.55	1.53	1.36	1.76	3.78	4.00	7.17	

Notes:-

- 1) The above Statement of consolidated and standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India. There is no minority interest.
- 2) The above Statement of consolidated and standalone unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 11, 2025 and have been reviewed by the Statutory Auditors of the Company who have expressed unmodified opinion.
- 3) The Company and the subsidiaries together referred to as "Group" are engaged primarily in the Pharmaceuticals business and there are no separate reportable segments as per Ind AS 108 on "Operating Segment Reporting".
- 4) During the quarter ended December 31, 2024, the Company has allotted 38,800 equity shares of Rs. 10 each fully paid up, on exercise of stock options by employees in accordance with the Company's Kopran Employee Stock Option Plan 2023.
- 5) Figures for the previous period have been regrouped or reclassified, wherever necessary to make them comparable with the figures of the current period.

Place : Mumbai
Date : February 11, 2025



FOR KOPRAN LIMITED

Surendra Somani
Executive Vice Chairman

KHANDELWAL JAIN & CO.

CHARTERED ACCOUNTANTS


6-B&C, Pil Court, 6th Floor,
111, M. Karve Road, Churchgate,
Mumbai - 400 020.

Tel.: (+91-22) 4311 5000
E-mail: kjco@kjco.net
Website: www.kjco.net

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of Kopran Limited Pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Kopran Limited

- 1) We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Kopran Limited ("the Parent" or "the Holding Company") and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") for the quarter and Nine months ended December 31, 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard - 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulation. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



-2-

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD 1144/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4) The Statement includes the results of the following entities:

Subsidiaries:

- Kopran Research Laboratories Limited
- Kopran Lifesciences Limited
- Kopran (H. K) Limited
- Kopran (UK) Limited (wholly owned subsidiary of Kopran Research Laboratories Limited)

5) Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6) (a). We did not review the interim financial information of 2 subsidiaries included in the Unaudited Consolidated Financial Results, whose interim financial information, before consolidation adjustments, reflect total income of Rs.9,435.21 lakhs and Rs.26,826.23 lakhs, total net profit after tax of Rs.273.77 lakhs and Rs.987.65 lakhs and total comprehensive income of Rs.275.93 lakhs and Rs.994.14 lakhs for the quarter and nine months ended December 31, 2024 respectively, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.



(b). The Unaudited Consolidated Financial Results includes the interim financial information of 2 subsidiaries which have not been reviewed by their auditors, whose interim financial information before consolidation adjustments, reflect total income of Rs. Nil and Rs. Nil, total net loss after tax of Rs.0.33 lakhs and Rs.2.00 lakhs and total comprehensive income of Rs.7.06 lakhs and Rs.5.99 lakhs for the quarter and nine months ended December 31, 2024, respectively, as considered in the Statement. According to the information and explanations given to us by the Management, this interim financial information are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For **KHANDELWAL JAIN & CO.**
Chartered Accountants,
Firm Registration No.: 105049W

Bhupendra Karkhanis

(Bhupendra Karkhanis)
PARTNER

Membership No.: 108336

UDIN: 25108336 BM JNLT3198



Place: Mumbai

Date: February 11, 2025

KHANDELWAL JAIN & CO.

CHARTERED ACCOUNTANTS

6-B&C, Pil Court, 6th Floor,
111, M. Karve Road, Churchgate,
Mumbai - 400 020.

Tel.: (+91-22) 4311 5000
E-mail: kjco@kjco.net
Website: www.kjco.net

Independent Auditor's Review Report on Unaudited Standalone Financial Results of Kopran Limited Pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of
Kopran Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Kopran Limited, ("the Company") for the quarter and nine months ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results, prepared in accordance



with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KHANDELWAL JAIN & CO.
Chartered Accountants,
Firm Registration No.: 105049W

Bhupendra Karkhanis

(Bhupendra Karkhanis)
PARTNER

Membership No.: 108336

UDIN: 25108336BMJNL57978



Place: Mumbai

Date: February 11, 2025

FORMAT FOR QUARTERLY INTEGRATED FILING (FINANCIAL)

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

- Not Applicable

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES

- NIL

S. No.	Particulars	in INR crore
1.	Loans / revolving facilities like cash credit from banks / financial institutions	-
A	Total amount outstanding as on date	-
B	Of the total amount outstanding, amount of default as on date	-
2.	Unlisted debt securities i.e. NCDs and NCRPS	-
A	Total amount outstanding as on date	-
B	Of the total amount outstanding, amount of default as on date	-
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	-

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

- Not Applicable

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

- Not Applicable